

Vemlidy[®] (tenofovir alafenamide)

Use in Fatty Liver Disease

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information. Some of the data may be outside of the US FDA-approved Prescribing Information. Gilead Sciences, Inc. does not intend to offer an opinion regarding the clinical relevance of these data or the advisability of administering any drug in a manner inconsistent with its approved labeling.

This document provides available information regarding Vemlidy[®] (tenofovir alafenamide [TAF]) for the treatment of chronic HBV and its use in patients with fatty liver disease (hepatic steatosis).

The full indication, important safety information, and boxed warnings are available at: https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf

Product Labeling¹

There is no information in the TAF product labeling regarding the treatment of subjects with comorbid fatty liver disease (hepatic steatosis).

Available Data

Study Design and Demographics²

A prospective, cohort study in participants with chronic HBV evaluated changes in liver stiffness measurements (LSM) and controlled attenuation parameter (CAP) measures in those who received TAF treatment for >12 months (N=67). Transient elastography was performed at baseline and Month 12.

Results²

Treatment with TAF for >12 months resulted in improvements in LSM but not steatosis (Figures 1 and 2).

Figure 1. LSM Categories at Baseline and Month 12²





Figure 2. CAP Measurements at Baseline and Month 12²



References

1. Enclosed. Gilead Sciences Inc, VEMLIDY® (tenofovir alafenamide) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.
2. Liang L, Wong V, Yip T, Tse Y, K., Hui V, Wong G. Changes of liver fibrosis and steatosis in patients with chronic hepatitis B receiving tenofovir alafenamide [Poster 773]. Paper presented at: American Association for the Study of Liver Diseases (AASLD) The Liver Meeting Virtual; 12-15 November, 2021.

Product Label

For the full indication, important safety information, and Boxed Warning(s), please refer to the VEMLIDY US Prescribing Information available at:

https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf.

Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 <http://www.askgileadmedical.com/>

Adverse Event Reporting

Please report all adverse events to:

Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statement) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.

VEMLIDY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© Gilead Sciences, Inc.